We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecule in Green Tea Used as Carrier for Anticancer Proteins

By LabMedica International staff writers
Posted on 16 Oct 2014
A molecule that is a key ingredient in green tea can be employed as a carrier for anticancer proteins, forming a stable and effective therapeutic nanocomplex. More...
This new discovery could help to construct better drug-delivery systems.

Some cancer treatments depend on medication comprising the therapeutic drug and a carrier that transports the drug to the tumor site. When designing drug carriers, several factors must be considered, for instance, it must be specific so that it only fights the tumor. Moreover, the drug-to-carrier ratio is important because using high quantities of the carrier could result in toxicity if the body cannot metabolize it. Furthermore, the complex will be ineffective if the body attacks and eliminates it too rapidly.

Joo Eun Chung and colleagues, from the Institute of Bioengineering and Nanotechnology (Singapore), used the molecule epigallocatechin-3-O-gallate (EGCG), which is found in high quantities in green tea, to create a carrier for the anticancer protein Herceptin. The advantage of EGCG over other carriers is that it also has anticancer effects.

The scientists injected the EGCG-Herceptin nanocomplex into mice and discovered that it showed better tumor selectivity and growth reduction, as well as lasting longer in the blood, which could increase its effectiveness than if Herceptin was injected alone.

The investigators published their findings published online October 5, 2014, in the journal Nature Nanotechnology.

Related Links:

Institute of Bioengineering and Nanotechnology



New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Repetitive Pipette
VWR® Stepper Pro
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.